ECRM_1170x120_8-1-17

Fitch Ratings

Walgreens Boots Alliance sees solid 3Q results

Walgreens Boots Alliance sees solid 3Q results

DEERFIELD, Ill. — Analysts said Walgreens Boots Alliance turned in a solid third quarter and stands to emerge on a positive note from its new deal with Rite Aid Corp. upon the termination of their merger. For the third quarter ended May 31, WBA posted net earnings (GAAP) of $1.16 billion, or $1.07 per diluted

Outlook: New landscape for drug chains?

Outlook: New landscape for drug chains?

NEW YORK — Entering the second quarter of 2017, the chain drug industry was awaiting answers to a couple of big, lingering questions. First, what will the chain drug landscape look like? A significant change in the field of players is likely in store pending antitrust clearance of Walgreens Boots Alliance Inc.’s (WBA’s) deal to

WBA makes $6 billion debt offering

WBA makes $6 billion debt offering

DEERFIELD, Ill. — Walgreens Boots Alliance (WBA) Inc. has announced a $6 billion debt offering to help finance its $17.2 billion deal to acquire Rite Aid Corp. WBA said late Thursday that it expects the underwritten public offering of unsecured, unsubordinated notes to close on June 1, pending customary closing conditions. The company reported that

AmerisourceBergen, Publix ink drug distribution pact

AmerisourceBergen, Publix ink drug distribution pact

VALLEY FORGE, Pa. — AmerisourceBergen Corp. has entered a long-term distribution deal with food and drug chain Publix Super Markets Inc. that includes branded, generic and over-the-counter pharmaceuticals. AmerisourceBergen said Thursday that the agreement includes direct delivery to Publix’s more than 980 pharmacies across the Southeast as well as its warehouse and central-fill facilities. The

Biologics are ramping up

Biologics are ramping up

Biologics are grabbing a larger share of drug development, according to Fitch Ratings. Food and Drug Administration approvals of biologic drugs represented 28% of all new drug approvals in the last 21 months, up from 17% over the 2010-13 period, Fitch revealed in its latest Global Pharmaceutical R&D Pipeline report. “Biologics will continue to take

Global consolidation rolls on in drug channel

Global consolidation rolls on in drug channel

McKesson’s deal to buy Ireland’s UDG Healthcare reflects the global consolidation of health care distribution, as drug wholesalers continue their drive for scale, especially in the realm of generic drugs, according to Fitch Ratings. “The UDG deal will add to McKesson’s generic purchasing power and further enhance its European pharmaceutical distribution presence, following its acquisition

PBM addition key for Rite Aid

PBM addition key for Rite Aid

Rite Aid’s acquisition of PBM EnvisionRx was seen by industry observers as a big plus for the drug chain. Fitch Ratings called the deal “a positive move as it will enable the company to expand its distribution channels by getting a foothold in the specialty and mail-order channels.” “The acquisition is supported by Rite Aid’s improved